A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 70 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
Phase of Trial: Phase III
Latest Information Update: 18 Feb 2019
At a glance
- Drugs Ibrutinib (Primary) ; Obinutuzumab (Primary) ; Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 11 Jan 2019 Status changed from not yet recruiting to recruiting.
- 01 Jan 2019 Planned initiation date changed from 19 Dec 2018 to 7 Jan 2019.
- 18 Nov 2018 New trial record